| Similar Articles |
|---|
 |
The Motley Fool
June 7, 2007
Brian Lawler |
Are You Ignoring the Most Exciting Stocks? Never considered drug stocks? You're missing some of the market's best investments.   |
The Motley Fool
January 28, 2008
Brian Lawler |
A Great Way to Recession-Proof Your Portfolio If you want a recession resistant portfolio, invest in large cap pharmaceuticals. |
The Motley Fool
February 22, 2010
Brian Orelli |
So Long, See You in Arbitration After another rejection, Johnson & Johnson and Basilea call it quits. |
The Motley Fool
October 24, 2006
Brian Lawler |
Amgen's Ho-Hum Quarter With all the money flowing into its coffers, the biotech has no excuse not to start paying a dividend. |
Managed Care
May 2004 |
Biologics Among Fastest Growers Managed care plans and pharmacy benefit managers can benefit from the strong generic presence in the market, but also face challenges relating to biotech drugs. |
The Motley Fool
January 26, 2010
Brian Orelli |
Timing Is Everything for Amgen Amgen is counting on osteoporosis drug Prolia for a successful 2010. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
September 15, 2010
Brian Orelli |
Drug Approved. Now Let's Sell This Baby! With ink still wet on its FDA approval, Savient continues its plan to find a buyer. |
The Motley Fool
August 18, 2010
Travers & Jayson |
The Most Important Thing About Human Genome Sciences Is Human Genome Sciences on strong financial footing? Take a look. |
The Motley Fool
January 27, 2011
Rich Smith |
What's Behind the Run-Up at Rexahn? The pharmaceutical's hot streak could soon burn up all its cash. |
The Motley Fool
January 26, 2011
Brian Orelli |
J&J Will Recover -- Someday Consumer health care might be the smallest of Johnson & Johnson's three divisions, but the 15% drop in revenue still hurts. A lot. |
The Motley Fool
April 29, 2011
Brian Orelli |
Show Us the Money, Drugmakers Drugmakers have cash and they aren't afraid to use it -- on themselves. |
The Motley Fool
September 27, 2010
Brian Orelli |
This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time. |
The Motley Fool
August 26, 2010
Travers & Jayson |
Will BioMarin Pharmaceutical Burn You? Is BioMarin Pharmaceutical on strong financial footing? |
The Motley Fool
August 12, 2010
Jordan DiPietro |
7 Burned-Out Drug Stocks These 5-star drug stocks have been beaten down to attractive levels. |
The Motley Fool
May 18, 2010
Brian Orelli |
What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout. |
The Motley Fool
August 10, 2010
Brian Orelli |
When the Disease Matters Most in Drug Approval Glaxo's and Valeant's Potiga will go before an FDA advisory committee tomorrow. |
The Motley Fool
October 12, 2004
Alyce Lomax |
Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson? |
The Motley Fool
February 28, 2011
Brian Orelli |
Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out? |
The Motley Fool
August 17, 2010
Travers & Jayson |
Interested in Cephalon ? Start Here! Every biotech company wants to discover the cure for cancer, Alzheimer's, or Wii knee. Every biotech investor hopes to catch the next Valeant Pharmaceuticals. |
The Motley Fool
May 7, 2008
Dan Caplinger |
Don't Buy These Stocks Now Many defensive stocks have gotten a lot more expensive. Take a look at some popular defensive plays and how they've performed over the past three months. |
The Motley Fool
May 20, 2011
Selena Maranjian |
Beware These "Very Attractive" ETFs There are some big red flags here. |
The Motley Fool
October 26, 2006
Brian Lawler |
Glaxo's Prescription for Sagging Sales Trading at roughly 32 times its trailing-12-month earnings, and with a solid 2.9% dividend yield, GSK is a fine investment for shareholders patient enough to wait until 2008 for a return to solid revenue growth. |
The Motley Fool
March 15, 2007
Brian Lawler |
It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers. |
The Motley Fool
August 18, 2010
Travers & Jayson |
Will Dendreon Burn You? You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big. Don't start with the science; ignore the sexy story, and look at the cold, hard cash. How does Dendreon stack up? |
The Motley Fool
March 31, 2011
Todd Wenning |
Dividend Sector Review: Pharmaceuticals These pharmaceutical stocks generate an adequate amount of free cash flow to fund their well above-average dividend yields. |
The Motley Fool
November 30, 2010
Travis Hoium |
Simcere Pharmaceutical Group Shares Popped: What You Need to Know Shares of Chinese drug company Simcere Pharmaceutical Group jumped 13% today after the company announced a fine at a company where it has controlling interest. |
The Motley Fool
January 28, 2010
Brian Orelli |
The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren. |
The Motley Fool
January 31, 2011
Brian Orelli |
Pharma Goes Back to School But will it produce more drugs? The pharmaceutical industry is headed back to school, with a number of large drugmakers announcing partnerships with universities. |
The Motley Fool
January 25, 2007
Brian Lawler |
Johnson & Johnson's Earnings Glee Johnson & Johnson keeps growing, even if the pharmaceutical segment is a bit sluggish. Investors, take note. |
The Motley Fool
November 8, 2011
Brian Wilson |
2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues. |
The Motley Fool
July 20, 2010
Brian Orelli |
Is J&J a Bad News Buy? Another quarter in 2010, another lowered earnings guidance for Johnson & Johnson. At least the year is half over for the health-care giant. |
The Motley Fool
October 17, 2006
Brian Lawler |
See Johnson & Johnson Crawl Earnings growth isn't moving right along because the company has become so big. Investors, take note. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
December 4, 2008
Brian Orelli |
Drug Deals Require Cash Pharmaceutical companies have been hoarding cash -- patiently waiting for good prices. And it looks like that time has arrived. Take a look at some players in the pharmaceutical field. |
The Motley Fool
June 27, 2008
Ryan Fuhrmann |
Recession-Proof Stocks: Johnson & Johnson This industry titan's stock is beaten down and should recover quite nicely when headwinds stop working against it and start to shift toward its back. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
July 16, 2010
Brian Orelli |
A Positive Sign for Pharma Earnings Season Strong first-half results drove Novartis to increase its sales guidance for the year. |
InternetNews
July 27, 2010 |
Oracle Debuts Drug-Tracking App for Big Pharma With its new Pedigree and Serialization Manager, Oracle is pitching an application to pharmaceutical companies that will enable them to track the movement of drugs across the supply chain. |
The Motley Fool
March 25, 2010
Brian Orelli |
More Than $5.3 Billion in Revenue Under Attack After dealing with the FDA, Amgen and J&J now have to deal with the Centers for Medicare & Medicaid Services. |
The Motley Fool
October 22, 2010
Anand Chokkavelu |
7 Big Pharma Stocks Near 52-Week Lows Trolling the bottom for upside potential. |
The Motley Fool
July 15, 2004
Brian Gorman |
Research Company's Stock Surges PPD's (formerly Pharmaceutical Product Development) second-quarter report isn't perfect, but long-term indicators look solid. The stock has risen as much as 14%. |
The Motley Fool
January 15, 2010
Brian Orelli |
The Odor Lingers at Johnson & Johnson The company has to recall products because of a smelly problem. |
The Motley Fool
May 7, 2010
Brian Orelli |
Drug Companies: Recession-Resistant, but Government-Proof? Greece decided to take action and forced drugmakers to reduce drug costs by an average of 21.5%. Investors need to think twice before making the seemingly sure bet on pharmaceutical companies. |
The Motley Fool
August 10, 2010
Brian Orelli |
Elan's Alternative to Strategic Alternatives Sometimes doing nothing is the best option. |
The Motley Fool
June 14, 2007
Ryan Fuhrmann |
Dueling Fools: GlaxoSmithKline Bear Glaxo is definitely a safe bet in the industry, and Avandia concerns have brought the share levels to even more reasonable levels. But investors can find the risk/reward trade-off even more compelling in other names. |
The Motley Fool
November 26, 2010
Brian Orelli |
Get It Together, Johnson & Johnson Another day, another recall. |
The Motley Fool
January 3, 2011
Rex Moore |
Highest-Yielding Pharma Stocks (You Might Actually Want to Buy) How to combine high yield with low risk. |
The Motley Fool
June 21, 2011
Alexander Crawford |
Bullish Biotech: 5 Biotech Firms Making Great Strides These five biotech firms have just received great news. Should they be on your watch list? |
The Motley Fool
October 19, 2011
Brian Orelli |
Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson. |
